title: Secondary acute promyelocytic leukemia: an increasingly common entity.
authors.forename: E
authors.initials: E
authors.lastname: Jantunen
authors.forename: K
authors.initials: K
authors.lastname: Heinonen
authors.forename: E
authors.initials: E
authors.lastname: Mahlamäki
authors.forename: K
authors.initials: K
authors.lastname: Penttilä
authors.forename: T
authors.initials: T
authors.lastname: Kuittinen
authors.forename: P
authors.initials: P
authors.lastname: Lehtonen
authors.forename: M
authors.initials: M
authors.lastname: Pyörälä
authors.forename: A
authors.initials: A
authors.lastname: Hänninen
authors.forename: T
authors.initials: T
authors.lastname: Nousiainen
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000188:drug therapy; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D011878:Radiotherapy / Q000009:adverse effects; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents